皮下曲前列尼尔治疗先天性心脏病相关肺动脉高压
这项观察性研究评估了皮下曲前列尼尔在成人先天性心脏病相关肺动脉高压(CHD-PAH)患者中治疗12个月的疗效与安全性。32例WHO功能III或IV级的晚期CHD-PAH患者接受了皮下曲前列尼尔治疗。结果显示6分钟步行距离平均增加114米(P<0.001),WHO功能分级显著改善(P=0.001),BNP从1259 pg/mL降至380 pg/mL(P=0.02),肺血管阻力显著下降(P=0.003)。最常见不良事件为输注部位红斑和疼痛,1例因疼痛停药,5例早期死亡。
要点
- 皮下曲前列尼尔可显著改善CHD-PAH患者的运动能力和WHO功能分级
- 治疗12个月时6分钟步行距离平均增加114米,肺血管阻力显著下降
- 输注部位红斑和疼痛是最常见不良事件,总体安全性可接受
核心结论
- 皮下曲前列尼尔治疗对CHD相关PAH的III和IV级患者通常安全有效,至少维持12个月。
研究设计与样本
- 观察性研究,连续纳入32例成人CHD-PAH患者(年龄40±10岁,20例女性),接受皮下曲前列尼尔滴定至最大耐受剂量。
主要发现
- 多变量混合模型显示,6分钟步行距离从基线至12个月平均增加114米(76; 152)(P<0.001)。
- WHO功能分级显著改善(P=0.001),B型脑钠肽从1259(375; 2368)pg/mL降至380(144; 1468)pg/mL(P=0.02)。
- 14例有治疗前后血流动力学数据的患者中,肺血管阻力从18.4±11.1 Wood单位显著降至12.6±7.9 Wood单位(P=0.003)。
- 最常见不良事件为输注部位红斑和疼痛,1例因不可耐受的输注部位疼痛在治疗8个月后停药,未观察到其他重大治疗相关并发症。
- 5例患者在早期随访中死亡,死亡前均出现6分钟步行距离下降。
临床怎么用
- 对于CHD-PAH且WHO功能III或IV级的成人患者,可考虑使用皮下曲前列尼尔治疗。
- 治疗期间需关注输注部位反应,部分患者可能因疼痛停药。
- 早期随访中6分钟步行距离下降可能提示不良预后。
局限性
- 观察性研究设计,无对照组。
- 血流动力学数据仅14例患者有治疗前后配对数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment. METHODS: Consecutive adult patients with CHD-PAH received subcutaneous treprostinil to maximum tolerated doses in an observational study. RESULTS: Advanced CHD-PAH patients with WHO class III or IV disease (n=32, age 40±10 years, 20 females) received treprostinil for suboptimal response to bosentan (n=12), WHO functional class IV disease (FC, n=7) or prior to bosentan approval (n=13). In the multivariate mixed model, mean increase in 6 min walk distance (6-MWD) from baseline to 12 months was 114 m (76; 152) (P<0.001). WHO FC improved significantly (P=0.001) and B-type brain natriuretic peptide decreased from 1259 (375; 2368) pg/mL to 380 (144; 1468) pg/mL (P=0.02). In those 14 patients who had haemodynamic data before and after initiation of treprostinil, pulmonary vascular resistance decreased significantly (from 18.4±11.1 to 12.6±7.9 Wood units, P=0.003). The most common adverse events were infusion-site erythema and pain. One patient stopped treatment because of intolerable infusion-site pain after 8 months of treatment. No other major treatment-related complications were observed. Five patients died during early follow-up, having experienced a decrease in their 6-MWD prior. CONCLUSIONS: Subcutaneous treprostinil therapy is generally safe and effective for at least 12 months and may be used in CHD-related PAH class III and IV.
引用
- Skoro-Sajer N, Gerges C, Balint OH, et al. Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension. Heart. 2018. PMID: 29436381. doi:10.1136/heartjnl-2017-312143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。